INTRODUCTION {#s1}
============

Endometrial cancer (EC) is the most common pelvic gynecological malignancy and the fourth leading cause of female cancer in occidental countries \[[@R1]\]. Although the majority of cases follows an indolent course and are cured by surgery alone, about 20% of patients recur and die by disease despite receiving adjuvant therapies \[[@R1]\]. Two mayor types of EC are distinguished based on epidemiology, histopathology and clinical behavior. Type I endometrioid EC, which is the most abundant (about 80%), arises in relatively younger women with a history of unopposed estrogenic stimulation, usually has differentiated or moderately differentiated histological grade with non-aggressive behavior. Type II non endometrioid EC (mostly papillary serous and clear cell), commonly occurs in older women with a background unrelated to unopposed estrogen exposure, usually is high grade and has worse prognosis \[[@R2], [@R3]\]. The endometrioid type frequently presents microsatellite instability (MSI), estrogen (ER) and progesterone (PR) receptors expression, *PTEN*, *K-ras* and *β-Catenin* mutations, epigenetic silencing of *APC* and a near diploid DNA content, although aneuploidy has also been detected in around 20% of this type \[[@R4]\]. In contrast, the non endometrioid type is mostly aneuploid, with lack or weak ER and PR expression, *p53* mutations and HER2 overexpression \[[@R2], [@R3]\].

MSI is present in the majority of tumors of the hereditary nonpolyposis colorectal cancer (HNPCC) syndrome, and also in a subset (15-20%) of sporadic tumors \[[@R5]-[@R8]\], that accumulate hundreds of thousands of somatic clonal mutations in simple repeat sequences (microsatellites) as a result of a defective mismatch repair (MMR) system \[[@R6], [@R9]\]. In colorectal cancer (CRC) MSI tumors exhibit pseudodiploidy and better outcome compared to tumors without MSI (MSS), which frequently are aneuploid \[[@R6], [@R9], [@R10]\]. In CRC, loss of expression of DNA double strand breaks repair proteins has been associated to increased aneuploidy and poorer survival \[[@R11]-[@R14]\]. Accordingly, three different pathways based on the combination of these two anomalies, namely, MSI-diploid, MSS-diploid and MSS-aneuploid, have been proposed to better stratify CRC according to clinical characteristics and outcome \[[@R15]-[@R17]\].

In EC MSI is mainly present in near-diploid tumors of endometrioid histology \[[@R3]\], and shows different gene mutation profile compared to gastrointestinal tumors of the mutator phenotype \[[@R18]-[@R20]\], associating with *K-ras* and *PTEN* mutations \[[@R3]\]. Published data about the clinical impact of MSI are conflicting \[[@R21]-[@R26]\], and recent studies have related aneuploidy to worse clinical behavior \[[@R4], [@R27], [@R28]\].

In this study, we tested whether MSI and aneuploidy could interfere when determining its influence on clinicopathological characteristics and outcome in endometrioid EC based on the inverse relationship found between MSI and aneuploidy, and the precedents about the clinical effect of the combination of these two genomic instability phenotypes in CRC.

RESULTS {#s2}
=======

In our series of 167 patients with endometrioid EC, all tumors with MSI presented *MLH1* promoter methylation and had a DNA-quasy-diploid content, and all aneuploid tumors were MSS. A single patient with presence of MSI and aneuploidy in the same tumor sample was excluded to simplify categories. Accordingly, tumors were divided in three categories: MSI, MSS-diploid and MSS-aneuploid. MSI and aneuploidy were detected in 33 (20%) and 24 (14%) cases respectively. The distribution of the subtypes according to demographic, surgicopathological and molecular variables of patients is shown in Table [1](#T1){ref-type="table"}.

###### MSI and ploidy status & demographic, surgico-pathological, and molecular characteristics of endometrioid endometrial cancer (EEC)

                                                                                                            MSI-diploid                                        MSS-diploid                                        MSS-aneuploid                                                  MSI vs MSS
  --------------------------------------------------------------------------------------------------- ----- -------------------------------------------------- -------------------------------------------------- -------------------------------------------------- ----------- ------------
  Age at diagnosis (years)[^1^](#tfn-006){ref-type="table-fn"}                                        167   67.3 ± 9.9                                         62.5 ± 9.4                                         62.2 ± 11.8                                        **0.040**   **0.035**
  BMI (kg/m^2^)                                                                                                                                                                                                                                                                  
   \<30                                                                                               66    21 (32) (64)[^b^](#tfn-003){ref-type="table-fn"}   37 (56) (34)[^b^](#tfn-003){ref-type="table-fn"}   8 (12) (33)[^b^](#tfn-003){ref-type="table-fn"}    **0.007**   **0.032**
   \>30                                                                                               101   12 (12) (36)                                       73 (72) (66)                                       16 (16) (67)                                                   
  Diabetes                                                                                                                                                                                                                                                                       
   no                                                                                                 125   22 (18)                                            84 (67)                                            19 (15)                                            \>0.1       
   yes                                                                                                42    11 (26)                                            26 (62)                                            5 (12)                                                         
  Hypertension                                                                                                                                                                                                                                                                   
   no                                                                                                 84    17 (20)                                            53 (63)                                            14 (17)                                            \>0.1       
   yes                                                                                                83    16 (19)                                            57 (69)                                            10 (12)                                                        
  Age of menarche (years)[^2^](#tfn-007){ref-type="table-fn"}                                         167   13 (11-19)                                         13 (9-18)                                          13 (10-17)                                         \>0.1       
  No. of births                                                                                                                                                                                                                                                                  
   \'0-1                                                                                              45    15 (33) (45)[^b^](#tfn-003){ref-type="table-fn"}   25 (56) (23)[^b^](#tfn-003){ref-type="table-fn"}   5 (11) (21)[^b^](#tfn-003){ref-type="table-fn"}    **0.016**   **0.023**
   \'2-3                                                                                              52    9 (17) (27)                                        34 (65) (31)                                       9 (17) (38)                                                    
   \'\>3                                                                                              70    9 (13) (27)                                        51(73) (46)                                        10 (14) (42)                                                   
  Total pregnancy months[^2^](#tfn-007){ref-type="table-fn"}^,^[^3^](#tfn-008){ref-type="table-fn"}   167   18 (0-81)                                          27 (0-126)                                         27 (0-90)                                          0.085       ns
  Menopause                                                                                                                                                                                                                                                                      
   no                                                                                                 17    2 (17)                                             10 (59)                                            5 (33)                                             \>0.1       
   yes                                                                                                150   31 (24)                                            100 (67)                                           19 (16)                                                        
  Age of menopause (years)[^2^](#tfn-007){ref-type="table-fn"}                                        150   52 (40-57)                                         51 (30-60)                                         48 (44-55)                                         **0.043**   ns
  Years of menstruation[^1^](#tfn-006){ref-type="table-fn"}^,^[^4^](#tfn-009){ref-type="table-fn"}    167   34.6 ± 5.5                                         32.2 ± 6.2                                         31.6 ± 4.9                                         0.087       ns
  Years from menopause to diagnosis[^1^](#tfn-006){ref-type="table-fn"}                               167   16.6 ± 10.7                                        13.1 ± 8.9                                         14.1 ± 11.1                                        \>0.1       
  Stage                                                                                                                                                                                                                                                                          
   I                                                                                                  115   16 (14) (16)[^c^](#tfn-004){ref-type="table-fn"}   86 (75)                                            13 (11) (13)[^d^](#tfn-005){ref-type="table-fn"}   **0.001**   
   II                                                                                                 27    8 (30) (30)                                        16 (59)                                            3 (11) (16)                                                    
   III                                                                                                25    9 (36) (53)                                        8 (32)                                             8 (32) (50)                                                    
  Grade                                                                                                                                                                                                                                                                          
   \'1                                                                                                88    14 (16) (17)[^c^](#tfn-004){ref-type="table-fn"}   68 (77)                                            6 (7) (8)[^d^](#tfn-005){ref-type="table-fn"}      **0.005**   
   \'2                                                                                                51    10 (20) (25)                                       30 (59)                                            11 (22) (27)                                                   
   \'3                                                                                                28    9 (32) (43)                                        12 (43)                                            7 (25) (37)                                                    
  Myometrial infiltration                                                                                                                                                                                                                                                        
   0-\<50%                                                                                            121   25 (21)                                            81 (67)                                            15 (12)                                            ns          
   \>50%                                                                                              46    8 (17)                                             29 (63)                                            9 (20)                                                         
  Vascular invasion                                                                                                                                                                                                                                                              
   no                                                                                                 122   18 (15) (16)[^c^](#tfn-004){ref-type="table-fn"}   92 (75)                                            12 (10) (12)[^d^](#tfn-005){ref-type="table-fn"}   **0.000**   
   yes                                                                                                45    15 (33) (45)                                       18 (40)                                            12 (27) (40)                                                   
  Treatment                                                                                                                                                                                                                                                                      
   surgery                                                                                            77    14 (18)                                            54 (70)                                            9 (12)                                             ns          
   surgery+radiotherapy                                                                               90    19 (21)                                            56 (62)                                            15 (17)                                                        
  ER (fmol/mg prot.)[^2^](#tfn-007){ref-type="table-fn"}                                              167   58 (0-280)                                         95 (0-737)                                         48 (0-376)                                         **0.032**   
  PgR (fmol/mg prot.)[^2^](#tfn-007){ref-type="table-fn"}                                             167   223 (0-1684)                                       330 (0-2069)                                       157 (0-1724)                                       ns          
  S-phase (percentaje)[^2^](#tfn-007){ref-type="table-fn"}                                            167   7.7 (0.4-24.0)                                     4.3 (0.7-21.4)                                     7.0 (1.2-24.7)                                     **0.000**   
  K-ras                                                                                                                                                                                                                                                                          
   wild-type                                                                                          143   20 (14)                                            102 (71)                                           21 (15)                                            **0.000**   
   mutant                                                                                             24    13 (54)                                            8 (33)                                             3 (13)                                                         
  PTEN                                                                                                                                                                                                                                                                           
   wild-type                                                                                          108   15 (14)                                            73 (68)                                            20 (19)                                            **0.010**   
   mutant                                                                                             59    18 (31)                                            37 (63)                                            4 (7)                                                          
  β-catenin                                                                                                                                                                                                                                                                      
   wild-type                                                                                          133   28 (21)                                            86 (65)                                            19 (14)                                            ns          
   mutant                                                                                             34    5 (15)                                             24 (71)                                            5 (15)                                                         
  APC                                                                                                                                                                                                                                                                            
   unmethylated                                                                                       109   10 (9)                                             84 (77)                                            15 (14)                                            **0.000**   
   methylated                                                                                         55    23 (42)                                            24 (44)                                            8 (15)                                                         

from binary logistic regression by comparing the MSI and MSS groups

n (%), unless otherwise specified

\% in the specified category

\% in diploid group

\% in MSS group

mean ± SD

median (range)

cases with uncomplete pregnancy were unknown

calculated as age of menopause or age at diagnoses for premenopausal women - age of menarche - number of births \* 1.125 ns = non significant

p=0.096

ER=estrogen receptor; PgR=progesterone receptor

p-values below 0.05 are in bold type

MSI tumors exhibited distinctive demographic features compared to MSS-aneuploid and MSS-diploid both of which shared similar features. Compared to MSS patients, those with MSI were older, relatively slim and had fewer births, in the multivariate analysis. Regarding clinico-pathological features, MSI and MSS-aneuploid tumors behaved similarly and exhibited marked differences compared to the MSS-diploid category. Thus, MSI and MSS-aneuploid tumors associated with advanced stage of progression (p=0.001) undifferentiated histological grade (p=0.005), and invasion of vascular space (p\<0.001). With respect to molecular parameters, MSI tumors had higher frequency of *K-ras* (p\<0.001) and *PTEN* (p=0.01) mutations, and *APC* promoter methylation (p\<0.001). MSI and MSS-aneuploid categories associated with high S-phase (p\<0.001).

Univariate survival analysis (summary in [Supplementary information, Tables S1 and S2](#SD1){ref-type="supplementary-material"}) of the whole series showed that MSI, aneuploidy, older age at diagnosis, advanced stage, higher grade, myometrial invasion, vascular invasion, and radiation therapy, among others, were associated with worse DFS and CSS. Survival curves of the whole series stratified according to the three defined categories showed significant better DFS and CSS for MSS-diploid tumors (Fig. [1](#F1){ref-type="fig"}). The potential of MSI and aneuploidy as prognostic markers was estimated by multivariate analyses in the whole series and in the diploid and MSS groups (Tables [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}). In the whole series, the basic multivariate DFS and CSS models included age at diagnosis, surgical stage and histological grade. After a stepwise procedure, MSI did not show significant prognostic value for DFS or CSS, and aneuploidy did for CSS (p=0.01).

![Kaplan-Meier curves for a) disease free survival and b) cancer-specific survival of the three categories of tumors defined by microsatellite instability and ploidy status in the whole series. Number of patients at risk, i.e. disease-free (a) or surviving (b), at time-points 0, 24, 48, 72, 96 and 120 months, are shown below the x-axis of each graph.](oncotarget-05-6206-g001){#F1}

###### Multivariate disease-free survival analysis of EEC according to MSI and ploidy

                Whole series[^1^](#tfn-010){ref-type="table-fn"}   Diploid tumors   MSS tumors   Whole series[^2^](#tfn-011){ref-type="table-fn"}                                                                                                                    
  ------------- -------------------------------------------------- ---------------- ------------ -------------------------------------------------- ------ ------ -------------------------------------- ------ ------ -------------------------------------- ------ ------
  Age (years)   1.0 (1.0-1.1)                                      4.1              0.04         1.1 (1.0-1.1)                                      4.4    0.04                                                 \-     1.0 (1.0-1.1)                          2.8    0.09
  Stage                                                                             0.00                                                                   0.02                                                 0.00                                                 0.00
   I            1[\*](#tfn-012){ref-type="table-fn"}                                             1[\*](#tfn-012){ref-type="table-fn"}                             1[\*](#tfn-012){ref-type="table-fn"}                 1[\*](#tfn-012){ref-type="table-fn"}          
   II           2.5 (1.0-6.2)                                      4.0              0.05         3.6 (1.3-10.1)                                     5.7    0.02                                                 0.72   2.7 (1.1-6.7)                          4.4    0.04
   III          8.2 (3.5-19.0)                                     23.8             0.00         6.9 (2.1-22.3)                                     10.4   0.01   11.8 (4.2-32.8)                        22.4   0.00   5.6 (2.3-13.8)                         14.3   0.00
  Grade                                                                             0.03                                                                   0.23                                                 0.03                                          5.5    0.06
   \'1          1[\*](#tfn-012){ref-type="table-fn"}                                                                                                              1[\*](#tfn-012){ref-type="table-fn"}                 1[\*](#tfn-012){ref-type="table-fn"}          
   \'2                                                                              0.15                                                                                                                        0.15                                                 0.40
   \'3          3.3 (1.4-8.2)                                      6.9              0.01                                                                          4.7 (1.4-15.2)                         6.5    0.01   2.9 (1.2-7.2)                          5.4    0.02
  MSI status                                                                                                                                                      NOT APPLICABLE                                                                                     
   MSS                                                                                           1[\*](#tfn-012){ref-type="table-fn"}                                                                                  1[\*](#tfn-012){ref-type="table-fn"}          
   MSI                                                                              0,15         2.9 (1.2-6.9)                                      5.6    0.02                                                        2.4 (1.0-5.9)                          3.6    0.05
  Ploidy                                                                                         NOT APPLICABLE                                                                                                                                                      
   Diploid                                                                                                                                                                                                             1[\*](#tfn-012){ref-type="table-fn"}          
   Aneuploid                                                                        0,29                                                                                                                        0,37   2.4 (1.0-6.4)                          2.8    0.09

MS status and ploidy were added separately to the basic model

MS status and ploidy were added at the same time to the basic model

Reference category

HR (95%CI) = hazard ratio (95% confidence interval)

###### Multivariate cancer-specific survival analysis of EEC according to MSI and ploidy

                Whole series[^1^](#tfn-013){ref-type="table-fn"}   Diploid tumors   MSS tumors   Whole series[^2^](#tfn-014){ref-type="table-fn"}                                                                                                                    
  ------------- -------------------------------------------------- ---------------- ------------ -------------------------------------------------- ------ ------ -------------------------------------- ------ ------ -------------------------------------- ------ --------
  Age (years)   1.0 (1.0-1.1)                                      5.9              0.02         1.1 (1.0-1.1)                                      3.8    0.05   1.1 (1.0-1.1)                          3.5    0.06   1.0 (1.0-1.1)                          5.5    0.02
  Stage                                                                             0.00                                                                   0.00                                                 0.00                                                 0.00
   I            1[\*](#tfn-015){ref-type="table-fn"}                                             1[\*](#tfn-015){ref-type="table-fn"}                             1[\*](#tfn-015){ref-type="table-fn"}                 1[\*](#tfn-015){ref-type="table-fn"}          
   II           3.3 (1.3-8.3)                                      6.7              0.01         3.6 (1.3-10.1)                                     5.7    0.02                                                 0.39   3.8 (1.5-9.6)                          7.7    0.00
   III          10.8 (4.7-24.8)                                    31.4             0.00         6.9 (2.1-22.3)                                     10.4   0.00   11.1 (3.9-31.1)                        20.8   0.00   7.5 (3.2-17.8)                         20.8   0.00
  Grade                                                                             0.00                                                                   0.02                                                 0.00                                                 0.00
   \'1          1[\*](#tfn-015){ref-type="table-fn"}                                             1[\*](#tfn-015){ref-type="table-fn"}                             1[\*](#tfn-015){ref-type="table-fn"}                 1[\*](#tfn-015){ref-type="table-fn"}          
   \'2          3.2 (1.3-8.3)                                      5.9              0.02         2.7 (0.9-8.2)                                      3.3    0.07   3.4 (1.0-11.4)                         3.8    0.05   2.5 (1.0-6.4)                          3.5    0.06
   \'3          7.1 (2.8-17.9)                                     16.8             0.00         4.7 (1.6-14.0)                                     7.9    0.00   8.8 (2.4-31.7)                         11.1   0.00   6.3 (2.5-16.1)                         14.7   0.01
  MSI status                                                                                                                                                      NOT APPLICABLE                                                                                     
   MSS          1[\*](#tfn-015){ref-type="table-fn"}                                             1[\*](#tfn-015){ref-type="table-fn"}                                                                                  1[\*](#tfn-015){ref-type="table-fn"}          
   MSI                                                                              0.36         3.0 (1.2-7.5)                                      5.5    0.02                                                        2.5 (1.0-6.2)                          3.9    \>0.05
  Ploidy                                                                                         NOT APPLICABLE                                                                                                                                                      
   Diploid      1[\*](#tfn-015){ref-type="table-fn"}                                                                                                                                                                   1[\*](#tfn-015){ref-type="table-fn"}          
   Aneuploid    2.7 (1.2-5.8)                                      6.2              0.01                                                                                                                        0,37   4.1 (1.6-11.2)                         9.0    0.00

MS status and ploidy were added separately to the basic model

MS status and ploidy were added at the same time to the basic model

Reference category

HR (95%CI) = hazard ratio (95% confidence interval)

In the DNA-diploid group, age, grade and stage were also present in the basic DFS and CSS models. When MSI was tested, it significantly associated with poor DFS (p=0.02) and CSS (p=0.02). In the MSS group, stage and grade for DFS, and age, stage and grade for CSS, were included in the basic model. Aneuploidy was not associated with DFS, but remained significant for CSS (p=0.02).

The significant prognostic value of MSI in the DNA-diploid group, and of aneuploidy in the MSS group, prompted us to estimate the impact of adding both variables simultaneously to the basic model in the whole series. As a result, MSI was significantly associated with poor DFS (p=0.05), and MSI and aneuploidy with worse CSS (p\<0.05 and p\<0.01, respectively). Thus, patients with MSI had an increased risk of recurrence and die by disease 2.4 (95% CI, 1.0 to 5.9) and 2.5 times (95% CI, 1.0-6.2) respectively, compared to MSS-diploid tumors.

The clinical impact of MSI was also assessed among the subgroup of patients treated with postoperative radiotherapy (RT) (Figure [2](#F2){ref-type="fig"}, univariate analyses are summarized in [Supplementary information, Table S3](#SD1){ref-type="supplementary-material"}). In the whole series of these treated patients, age, stage and grade, and in the DNA-diploid group, age and stage, were incorporated in the basic model for DFS and CSS. According to the multivariate analysis, MSI lacked independent value for DFS and CSS in the whole series. However, in the group of diploid tumors, MSI predicted worse DFS (p=0.02) and CSS (p=0.04) (Table [4](#T4){ref-type="table"}).

![Kaplan-Meier curves for a) disease free survival and b) cancer-specific survival of EC patients with diploid tumors (MSS or MSI) who were treated with radiotherapy](oncotarget-05-6206-g002){#F2}

###### Multivariate survival analysis for MSI after treatment with radiotherapy

                Disease-free survival   Cancer-specific survival                                                                                              
  ------------- ----------------------- -------------------------- ------ ---------------- ----- ------ ---------------- ------ ------ ---------------- ----- ------
  Age (years)   1.0 (1.0-1.1)           3.0                        0.08   1.1 (1.0-1.1)    3.7   0.06   1.1 (1.0-1.1)    6.0    0.01   1.1 (1.0-1.1)    4.6   0.03
  Stage                                                            0.03                          0.30                           0.00                          0.07
   I            1\*                                                                                     1\*                            1\*                    
   II                                                              0.17                                 2.6 (0.9-7.8)    3.0    0.08   4.1 (1.1-14.9)   4.7   0.03
   III          4.5 (1.5-13.3)          7.1                        0.01                                 7.5 (2.5-22.9)   12.5   0.00   4.1 (0.9-20.0)   3.2   0.07
  Grade                                                            0.16                          \-                             0.06                          \-
   \'1                                                                                                  1\*                                                   
   \'2                                                                                                                          0.21                          
   \'3                                                                                                  3.9 (1.3-11.7)   5.7    0.02                          
  MS status                                                                                                                                                   
   MSS                                                                    1\*                                                          1\*                    
   MSI                                                             0,23   3.6 (1.2-10.7)   5.4   0.02                           0.73   3.4 (1.1-11.1)   4.2   0.04

Reference category

HR (95%CI) = hazard ratio (95% confidence interval)

DISCUSSION {#s3}
==========

In EC MSI and aneuploidy appear as mutually exclusive genomic alterations with clinical implications, although clinical data regarding MMR deficiency remain conflicting. In this work we hypothesized whether the clinical relevance of MSI in endometrioid EC could be clarified by studying this genetic alteration under the perspective of three alternative genomic cancer pathways, namely, MSI, MSS-diploid, and MSS-aneuploid. The clear known differences between endometrioid and non-endometrioid tumors \[[@R2], [@R3]\] justify the exclusion of non-endometrioid tumors from our study, since they can act as a confounding factor \[[@R26]\]. Another circumstance that added homogeneity to the stratification of our series is that all MSI tumors were diploid and had *MLH1* promoter methylation. This refers to a non-hereditary origin \[[@R29]\], especially relevant when studying the relationship between MSI and, at least, some demographic variables.

Patient age, obesity and nulliparity are three known EC risk factors. Although previous studies failed to find any relation between MSI and age \[[@R22], [@R24]\], it has been shown that women displaying MSI and methylated *MLH1* are significantly older \[[@R30], [@R26]\]. This agrees with our observations and with the fact that *MLH1* methylation is known to be an age related phenomena \[[@R31]-[@R33]\]. The inverse relationship between MSI and BMI is in accordance to other reports \[[@R30]\]. In CRC the association between MSI and nulliparity has also been published \[[@R32]\]. Although a connection between estrogen exposure and reduced risk of acquiring MMR deficiency has been suggested \[[@R32], [@R34]\], further studies are required to elucidate the molecular bases.

In the whole series, MSI cases associated with higher FIGO grade, advanced surgical stage and lymphovascular invasion compared to MSS-diploid tumors. For each clinical feature, several groups have reported similar results, either in EC, without distinction of histological types, or in the endometrioid subtype \[[@R24], [@R26]\], although discordant findings have also been published \[[@R22], [@R24], [@R30], [@R26]\]. In CRC, the association between MSI and poor differentiated grade is well established \[[@R10]\]. Our data show that MSI might manifest in clones with undifferentiated aggressive appearing histology among tumors with a background of DNA-diploid content. MSS-aneuploid subtype tumors had pathological features similar to those of MSI tumors, since they frequently presented higher grade, advanced stage and vascular involvement. The association of aneuploidy with a more aggressive clinical phenotype in EC is well documented \[[@R4], [@R27], [@R28]\]. According to our data, MSS-diploid tumors display a more benign phenotype (differentiated grade, early stage and absence of vascular invasion) compared to MSI and MSS-aneuploid tumors.

We found that MSI tumors were more likely to present lower ER levels and a trend towards lower PgR, which contrast with the fact that endometrioid tumors are prototypically associated with estrogen stimulation and generally express both receptors \[[@R2]\]. The reason for this observation could be the high prevalence of MSI in poor differentiated grades, since most high grade EC show weak ER and PgR expression \[[@R2]\]. In CRC, either arising in Lynch syndrome families or not, significantly lower hormone receptor levels have been described in MSI tumors \[[@R35], [@R36]\].

Our EC MSI tumors also showed increased S-phase compared to MSS-diploid tumors. In this line, cyclin A, which is necessary for DNA replication and S-phase entry, has also been related to the MSI phenotype and to cell proliferation in EC \[[@R37], [@R38]\].

As previously reported \[[@R39], [@R40], [@R3]\], our results show that MSI was positively related to *K-ras* and *PTEN* mutations and *APC* promoter hypermethylation, whereas inversely associated with *β-catenin* mutations. It is well known that in CRC the association of MSI with these molecular variables is quite different. For example, *K-ras* mutations mainly coexist with MSS tumors, while *β-catenin* mutations and *APC* promoter methylation are characteristic of MSI tumors \[[@R6], [@R41], [@R42]\].

The absence of a significant impact of MSI on survival was recently reported by Zighelboim et al \[[@R26]\] and by others previously in endometrioid EC, and by Basil et al \[[@R21]\] and McDonnald et al \[[@R22]\], among others, in EC (endometrioid and non-endometrioid). Conversely, several groups have referred an association of MSI with better \[[@R23], [@R24]\], or worse \[[@R25]\] outcome in series including only endometrioid tumors or both histological types. As for the prognostic value of ploidy in EC, latest publications suggest that is a statistically independent prognosticator of poor outcome through multivariate analysis \[[@R4], [@R27], [@R28]\].

Our most relevant finding in the multivariate survival analysis was that both MSI and aneuploidy remained as significant prognosticators of worse DFS and CSS when aneuploidy and MSI where, respectively, excluded from the corresponding survival analyses. In the whole series, the simultaneous inclusion of both variables influenced their respective outcome values, making (marginally) significant its relationship with DFS, and significant its contribution to CSS. This suggests that when analysing the prognostic value of MSI or aneuploidy, each variable could act as a confounding factor for the other. It is noteworthy that the number of recurrences (40%) and death (44%) of patients with MSI EC tumors in our series was higher than previously reported by some studies \[[@R22]-[@R24], [@R26]\]. In CRC, the interference between these variables in clinical outcome has also been proposed, and cumulative evidence associates MSI-diploidy with good prognosis \[[@R16], [@R17]\]. The strong local and systemic antitumoral immune response observed in MSI CRC have been proposed as a possible mechanism to explain the increased survival rates in patients with MSI tumors \[[@R43]\]. However, in endometrioid EC, Risinger et al \[[@R44]\] reported that significant differences in tumor infiltrating lymphocytes derived transcripts, do not occur between tumors with and without MSI. Therefore, a relevant task for future research will be to elucidate the mechanism beneath the different immune response of CRC and EC with MSI, and why the influence of MSI-diploidy on patient\'s survival in EC is just the opposite of that observed in CRC.

Finally, we have also observed that among diploid tumors, MSI predicts worse DFS and CSS in patients treated with postoperative RT. We have previously suggested the predictive role of MSI in early staged radiation-treated endometrioid EC \[[@R45]\]. There are few related studies, mostly in preoperative RT rectal treated tumors, and with discordant results \[[@R46]-[@R48]\]. As previously pointed, the worse response of MSI tumors to RT could be related to the suggested increased malignant potential of *MLH1* null mice after ionizing radiation exposure due to the activation of mitotic recombinational events \[[@R49]\].

Due to the combination of low incidence of MSI and aneuploidy and of recurrences and cancer-specific deaths inherent to this non-aggressive endometrial cancer type, the present work has limited statistical power. Nevertheless, there was sufficient data (at least 5 events for each explanatory variable) to get reproducible results from multivariate regression analysis. Future work thus seems warranted, as it may assist to a better stratification of patients for election of modality of treatment. In summary, our data show that the three groups described here based on MSI status and ploidy might represent different molecular pathways of tumorigenesis and progression of endometrioid endometrial cancer with different prognostic and predictive significance.

MATERIALS AND METHODS {#s4}
=====================

Study Participants and Clinical Data {#s4_1}
------------------------------------

A series of 167 patients with endometrioid EC (surgical stage I-III), was selected from a previously described Caucasian population-based series of 204 patients with EC, diagnosed and treated between 1990 and 1999 \[[@R40]\]. Exclusion causes from the original EC series were: non endometrioid histology, fulfill the Amsterdam criteria of HNPCC and lack of fresh tumor sample to perform flow cytometry. A single patient with presence of MSI and aneuploidy in the same tumor sample was also excluded.

Clinico-pathological data of patients were prospectively collected and computerized. Surgical stage and tumor grade were assigned according to the International Federation of Gynecology and Obstetrics (FIGO) 1988 criteria. None of the patients received preoperative radiation or chemotherapy. All patients underwent exploratory laparatomy, total hysterectomy and bilateral salpingo-oophorectomy. Lymphadenectomy was performed at the discretion of the surgeon. Radiation therapy after surgery was administered to most of stage II and III patients and to stage I patients with risk factors as deep myometrial invasion and high histological grade. The treatment consisted of irradiation of either the vaginal cuff (45-60 Gy), the whole pelvis (50 Gy), or both. A few patients received irradiation in the whole pelvis and in the para-aortic nodes (45 Gy). Only 4 patients received adjuvant chemotherapy in addition to radiotherapy. Forty non-cancerous endometrial samples were used as control tissue in methylation analysis. The study was approved by the institutional ethical committee and all subjects provided informed consent.

Tissue fractionation, DNA isolation and molecular analyses {#s4_2}
----------------------------------------------------------

Frozen tumor specimens were macroscopically dissected to enrich for neoplastic cellularity. The tissue was mechanically disrupted and the sub-cellular fractions (cytosolic and nuclear) were obtained as previously described \[[@R50]\]. DNA was extracted by a standard procedure. DNA was also obtained from matching peripheral blood leukocytes and from non-tumoral endometrial tissues.

For MSI classification, five quasi monomorphic mononucleotide markers BAT25, BAT26, NR21, NR24 and NR27 were used according to published conditions and criteria \[[@R51], [@R45]\]. Tumors were considered MSI when they showed alterations in at least 2 out of five markers. Ninety seven percent of MSI tumors (all but one) were correctly classified by using only BAT-26 and BAT-25. Tumors with only one altered marker (n=12) were classified as MSS \[[@R52]\].

Promoter methylation analysis of *hMLH1* gene was performed by methylation-specific PCR (MSP) \[[@R53]\], using previously reported primers and conditions \[[@R42], [@R54]\]. Methylation of the analyzed *MLH1* promoter region invariably correlates with absence of gene expression \[[@R55]\].

Ploidy status and S-phase fraction were estimated by flow cytometry as previously reported \[[@R50]\]. Tumors with a DNA index \> 0.9 and \< 1.1 were classified as "(quasi)diploid" and others as aneuploid.

Single strand conformation polymorphism (SSCP) and DNA sequencing analyses were applied to search for mutations in K-*ras* (exons 1 and 2), *PTEN* (exons 1 to 9 and intronic splice sites) and *β-catenin* (*CTNNB1*) (exon 3 mutations and intragenic deletions). Analyses of *PTEN* and *β-catenin* were as described elsewhere \[[@R41], [@R40]\]. Primer sequences and conditions for *K-ras* mutation analysis are available upon request. Promoter methylation analysis of *APC* was performed by methylation-specific PCR (MSP) \[[@R53]\], using previously reported primers and conditions \[[@R42], [@R54]\]. Quantification of estrogen (ER) and progesterone (PR) receptors was done using the labeled hormone exchange method as described \[[@R50]\].

Follow-up {#s4_3}
---------

All patients were routinely followed at 3-month intervals the first 2 years, 6 months until the fifth year, and every year thereafter. Three patients lost in less than 6 months after surgery were excluded. Disease-free survival (DFS) was defined as the time from surgery to recurrence for patients with a disease-free interval after surgery, and cancer-specific survival (CSS) as the time from surgery to cancer-related death. Patients with persistent disease after surgery (n=9) were excluded from DFS analysis. Patients that died by causes other than disease (n=10) were censored at the date of death. The median follow-up was 112 months (range 6-227 months) for all patients and 132 months (range 16-227 months) for patients that did not die by disease.

Statistical analyses {#s4_4}
--------------------

The relationship among categories established by MSI and ploidy status and categorical variables was analyzed by Chi-square test. ANOVA was used for variables with a Gaussian distribution, and Kruskal-Wallis test for variables with a non-normal distribution. Binary logistic regression analysis was employed to test the independent contribution of demographic variables to MSI development. Survival curves were prepared according to Kaplan-Meier method and compared by the log--rank test. Univariate and multivariate survival analysis was carried out using the Cox proportional hazard model. Demographic and surgicopathological (including treatment) variables were entered to discern their independent contribution to the basic regression model for the multivariate survival analyses. A forward stepwise method was used to test the influence of explanatory variables (with a p-value \< 0.1 in the univariate analysis) in the multivariate regression studies. The analysis of independence was performed by likelihood ratio tests. All analyses were two sided, and statistical significance was set at a p-value \< 0.05. Analyses were carried out using the PASW (version 18.0) statistical package (SPSS, Chicago, IL).

SUPPLEMENTARY MATERIAL AND TABLES
=================================

Grant sponsors: ICIC, Fundación Canaria de Investigación y Salud (FUNCIS), Agencia Canaria de Investigación, Innovación y Sociedad de la Información del Gobierno de Canarias (CB, JCD-C), and Fondo Investigaciones Sanitarias of the Instituto de Salud Carlos III (grant FIS PS09/02444).

This paper has been accepted based in part on peer-review conducted by another journal and the authors\' response and revisions as well as expedited peer-review in Oncotarget

The authors declare no conflicts of interest.
